Molecule Details
| InChIKey | FEJVSJIALLTFRP-LJQANCHMSA-N |
|---|---|
| Compound Name | Darusentan |
| Canonical SMILES | COc1cc(OC)nc(O[C@H](C(=O)O)C(OC)(c2ccccc2)c2ccccc2)n1 |
| Clinical Status | Data-mined Candidate |
| Targets (Human+Pathogen) | 2 |
| Pfam Stratification | Homologous |
| Avg pChEMBL | 7.33 |
| Source | ChEMBL;BindingDB |
2D Structure
Activity Profile
DrugBank Annotations
| DrugBank ID | DB04883 |
|---|---|
| Drug Name | Darusentan |
| CAS Number | 171714-84-4 |
| Groups | investigational |
| ATC Codes | nan |
| Description | Darusentan is a selective endothelin ETA receptor antagonist. It is being evaluated as a treatment for congestive heart failure and hypertension. |
Categories: Acids, Carbocyclic Endothelin Receptor Antagonists
Cross-references: BindingDB: 50108202 CHEMBL23261 ChemSpider: 154336 PubChem:177236 PubChem:175426886 Wikipedia: Darusentan ZINC: ZINC000003826221
Target Activities (2)
DrugBank Target Actions (1)
| Target | Gene | Target Name | Action | Type |
|---|---|---|---|---|
| P25101 | EDNRA | Endothelin-1 receptor | antagonist | targets |